CY2017025I2 - Αντιδοτα αντιπηκτικων - Google Patents

Αντιδοτα αντιπηκτικων

Info

Publication number: CY2017025I2
Authority: CY; Cyprus
Prior art keywords: anticoagulants; antibodies
Prior art date: 2010-01-20

Application number

CY2017025C

Other languages

English (en)

Other versions

CY2017025I1 (el

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-20

Filing date

2017-07-10

Publication date

2017-11-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2017025(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-07-10 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2017-11-14 Publication of CY2017025I1 publication Critical patent/CY2017025I1/el

2017-11-14 Publication of CY2017025I2 publication Critical patent/CY2017025I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Mycology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CY2017025C 2010-01-20 2017-07-10 Αντιδοτα αντιπηκτικων CY2017025I2 (el)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP10151239		2010-01-20
US38391410P	2010-09-17	2010-09-17
PCT/EP2011/050749 WO2011089183A2 (en)	2010-01-20	2011-01-20	Anticoagulant antidotes
EP11703410.8A EP2525812B1 (en)	2010-01-20	2011-01-20	Anticoagulant antidotes

Publications (2)

Publication Number	Publication Date
CY2017025I1 CY2017025I1 (el)	2017-11-14
CY2017025I2 true CY2017025I2 (el)	2017-11-14

Family

ID=42061991

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20171100361T CY1118875T1 (el)	2010-01-20	2017-03-22	Αντιδοτα αντιπηκτικων
CY2017025C CY2017025I2 (el)	2010-01-20	2017-07-10	Αντιδοτα αντιπηκτικων

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20171100361T CY1118875T1 (el)	2010-01-20	2017-03-22	Αντιδοτα αντιπηκτικων

Country Status (43)

Country	Link
US (3)	US8486398B2 (el)
EP (2)	EP3195876A1 (el)
JP (2)	JP5575923B2 (el)
KR (1)	KR101781787B1 (el)
CN (1)	CN102711813B (el)
AP (1)	AP2012006242A0 (el)
AR (1)	AR079944A1 (el)
AU (1)	AU2011208719C1 (el)
BR (1)	BR112012018021B1 (el)
CA (1)	CA2787566A1 (el)
CO (1)	CO6571889A2 (el)
CY (2)	CY1118875T1 (el)
DK (1)	DK2525812T3 (el)
EA (1)	EA028371B1 (el)
EC (1)	ECSP12012105A (el)
ES (1)	ES2614992T3 (el)
FR (1)	FR17C1026I2 (el)
GE (1)	GEP20156341B (el)
HR (1)	HRP20170613T1 (el)
HU (2)	HUE032263T2 (el)
IL (1)	IL219427B (el)
LT (2)	LT2525812T (el)
LU (1)	LUC00028I2 (el)
MA (1)	MA33936B1 (el)
ME (1)	ME02602B (el)
MX (1)	MX2012008360A (el)
MY (1)	MY162323A (el)
NL (1)	NL300882I2 (el)
NO (2)	NO2017034I1 (el)
NZ (1)	NZ599508A (el)
PE (1)	PE20121516A1 (el)
PH (1)	PH12012501493A1 (el)
PL (1)	PL2525812T3 (el)
PT (1)	PT2525812T (el)
RS (1)	RS55683B1 (el)
SG (1)	SG182552A1 (el)
SI (1)	SI2525812T1 (el)
TN (1)	TN2012000366A1 (el)
TW (1)	TWI513466B (el)
UA (1)	UA110470C2 (el)
UY (1)	UY33196A (el)
WO (1)	WO2011089183A2 (el)
ZA (1)	ZA201202876B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI513466B (zh) *	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑
CA3027071A1 (en)	2011-01-14	2013-07-19	The Regents Of The University Of California	Therapeutic antibodies against ror-1 protein and methods for use of same
JP2014506448A (ja) *	2011-01-19	2014-03-17	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	凝固因子の阻害剤に対する結合タンパク質
CA2827787A1 (en)	2011-03-30	2012-10-04	Boehringer Ingelheim International Gmbh	Anticoagulant antidotes
PE20141295A1 (es)	2011-11-29	2014-10-01	Perosphere Inc	Agentes de reversion anticoagulante
HK1215261A1 (zh)	2013-03-14	2016-08-19	Bayer Healthcare Llc	針對與肝素複合的抗凝血酶β的單克隆抗體
EP3060583A1 (en) *	2013-10-25	2016-08-31	Boehringer Ingelheim International GmbH	Anticoagulant antidotes
TW201623331A (zh) *	2014-03-12	2016-07-01	普羅帝納生物科學公司	抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN105223348A (zh) *	2014-05-26	2016-01-06	北京九强生物技术股份有限公司	人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) *	2014-07-30	2016-02-03	Rheinische Friedrich-Wilhelms-Universität Bonn	Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
EP3611507B1 (en) *	2014-07-31	2021-11-24	Haemonetics Corporation	Detection of reversal of an anticoagulant using ecarin and factor xa clotting assays
WO2016044645A1 (en) *	2014-09-17	2016-03-24	Elmaleh David R	Anticoagulant derivatives for cardiovascular imaging
WO2016107605A1 (zh)	2014-12-31	2016-07-07	昆明积大制药股份有限公司	药物组合物及其制备方法
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
US11879014B2 (en)	2017-03-17	2024-01-23	Tusk Therapeutics Ltd.	Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
JP7233720B2 (ja) *	2017-12-24	2023-03-07	ノイルイミューン・バイオテック株式会社	ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞
SG11202008733YA (en)	2018-03-13	2020-10-29	Tusk Therapeutics Ltd	Anti-cd25 for tumour specific cell depletion
KR20210039985A (ko) *	2018-05-11	2021-04-12	헬시언 테라퓨틱스 인코포레이티드	Gasp-1 과립을 표적으로 하는 결합 단백질 및 키메라 항원 수용체 t 세포, 및 이의 용도
CN113195515B (zh)	2018-10-29	2024-11-15	丽珠医药集团股份有限公司	新的二肽类化合物及其用途
US12251377B2 (en)	2019-03-06	2025-03-18	University Of Rochester	Anticoagulant compositions and uses thereof
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
TW202321311A (zh) *	2021-08-02	2023-06-01	日商諾伊爾免疫生物科技股份有限公司	與scFv等之連接子結合的抗體
US11446286B1 (en) *	2022-02-28	2022-09-20	King Faisal University	Treatment of fungal infections using dabigatran etexilate
NL2036011B1 (en)	2023-10-12	2025-04-30	Synapse Res Institute	Molecules for reversing anti-coagulant activity of direct oral anticoagulants
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en)	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
EP0281604B1 (en)	1986-09-02	1993-03-31	Enzon Labs Inc.	Single polypeptide chain binding molecules
ATE102631T1 (de)	1988-11-11	1994-03-15	Medical Res Council	Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
EP0654085B1 (en) *	1992-01-23	1997-04-02	MERCK PATENT GmbH	Monomeric and dimeric antibody-fragment fusion proteins
DE4203965A1 (de)	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
DE69330523D1 (de)	1992-08-21	2001-09-06	Vrije Universiteit Brussel Bru	Immunoglobuline ohne leichte ketten
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
CA2163032C (en)	1993-06-03	2001-02-06	John Landon	Antibody fragments in therapy
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
WO1998049198A1 (en)	1997-04-30	1998-11-05	Enzon, Inc.	Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
DE19729544A1 (de) *	1997-07-10	1999-01-14	Basf Ag	Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
EP2275557A1 (en)	2000-04-12	2011-01-19	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2316951A1 (en)	2001-01-17	2011-05-04	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en)	2001-04-16	2004-05-20	Taveras Arthur G.	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20070031438A1 (en) *	2001-12-10	2007-02-08	Junghans Richard P	Antibodies as chimeric effector cell receptors against tumor antigens
AU2002351896A1 (en)	2001-12-11	2003-06-23	Ablynx N.V.	Method for displaying loops from immunoglobulin domains in different contexts
AU2003244817B2 (en)	2002-06-28	2010-08-26	Domantis Limited	Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP2006519763A (ja)	2002-11-08	2006-08-31	アブリンクスエン．ヴェー．	治療用ポリペプチドの投与法およびそのためのポリペプチド
DE602004017726D1 (de)	2003-06-30	2008-12-24	Domantis Ltd	Pegylierte Single-domain-antikörper (dAb)
DK2915564T3 (da)	2007-09-28	2021-02-08	Alexion Pharma Inc	Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
AR070141A1 (es) *	2008-01-23	2010-03-17	Glenmark Pharmaceuticals Sa	Anticuerpos humanizados especificos para el factor von willebrand
BR112012004169A2 (pt)	2009-08-24	2016-03-29	Boehringer Ingelheim Int	intervenções de emergência com carvão vegetal ativado em superdosagem de etexilato de dabigatran
TWI513466B (zh) *	2010-01-20	2015-12-21	Boehringer Ingelheim Int	抗凝血劑解毒劑

2011
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/en not_active Withdrawn
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active Active
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/en active Active
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/me unknown
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 PH PH1/2012/501493A patent/PH12012501493A1/en unknown
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 CA CA2787566A patent/CA2787566A1/en not_active Abandoned
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/en not_active Ceased
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
2013
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-10 CY CY2017025C patent/CY2017025I2/el unknown
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown

Also Published As

Publication number	Publication date
MY162323A (en)	2017-05-31
SI2525812T1 (sl)	2017-05-31
CO6571889A2 (es)	2012-11-30
PE20121516A1 (es)	2012-11-24
FR17C1026I1 (fr)	2017-09-08
LTPA2017021I1 (lt)	2017-07-25
AU2011208719C1 (en)	2017-07-13
US8486398B2 (en)	2013-07-16
US20130289248A1 (en)	2013-10-31
NZ599508A (en)	2014-05-30
PH12012501493A1 (en)	2012-10-22
HUE032263T2 (en)	2017-09-28
ME02602B (me)	2017-06-20
EP2525812A2 (en)	2012-11-28
UA110470C2 (ru)	2016-01-12
DK2525812T3 (en)	2017-02-27
HK1173957A1 (en)	2013-05-31
PT2525812T (pt)	2017-04-26
WO2011089183A2 (en)	2011-07-28
TN2012000366A1 (en)	2014-01-30
AP2012006242A0 (en)	2012-04-30
MA33936B1 (fr)	2013-01-02
HRP20170613T1 (hr)	2017-06-30
TW201136606A (en)	2011-11-01
US20120027780A1 (en)	2012-02-02
CY1118875T1 (el)	2018-01-10
CN102711813A (zh)	2012-10-03
CY2017025I1 (el)	2017-11-14
US9034822B2 (en)	2015-05-19
US20150210778A1 (en)	2015-07-30
LTC2525812I2 (lt)	2019-05-10
ECSP12012105A (es)	2012-10-30
BR112012018021A2 (pt)	2017-06-20
CN102711813B (zh)	2015-03-04
PL2525812T3 (pl)	2017-07-31
KR20120128126A (ko)	2012-11-26
LUC00028I1 (el)	2017-07-14
EP3195876A1 (en)	2017-07-26
HUS1700030I1 (hu)	2017-08-28
JP5575923B2 (ja)	2014-08-20
CA2787566A1 (en)	2011-07-28
NO2022036I1 (no)	2022-08-12
EA201201016A1 (ru)	2013-02-28
EA028371B1 (ru)	2017-11-30
AU2011208719A1 (en)	2012-05-17
ZA201202876B (en)	2012-12-27
UY33196A (es)	2011-08-31
NO2017034I1 (no)	2017-07-11
IL219427B (en)	2018-05-31
TWI513466B (zh)	2015-12-21
JP2014210794A (ja)	2014-11-13
FR17C1026I2 (fr)	2018-07-20
LUC00028I2 (el)	2017-09-25
EP2525812B1 (en)	2017-01-18
NL300882I2 (nl)	2017-07-20
JP2013517317A (ja)	2013-05-16
KR101781787B1 (ko)	2017-09-26
ES2614992T3 (es)	2017-06-02
LT2525812T (lt)	2017-02-27
MX2012008360A (es)	2012-08-08
WO2011089183A3 (en)	2011-11-17
IL219427A0 (en)	2012-06-28
AR079944A1 (es)	2012-02-29
RS55683B1 (sr)	2017-07-31
SG182552A1 (en)	2012-08-30
GEP20156341B (en)	2015-08-10
BR112012018021B1 (pt)	2020-12-08

Publication	Publication Date	Title
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
CY2017025I2 (el)	2017-11-14	Αντιδοτα αντιπηκτικων
CY2019040I1 (el)	2020-05-29	Aνti-il-23 αντισωματα
LTC2579894I2 (lt)	2020-03-25	CGRP antikūnai
HUE056313T2 (hu)	2022-02-28	Anti-DLL3 antitest
BR112012030311A2 (pt)	2017-01-24	anticorpo
IL222272B (en)	2018-04-30	Anti-erbb3 antibodies
DK3741883T3 (da)	2023-02-20	Antistofbiblioteker
DK3284754T3 (da)	2020-12-21	Anti-cd38-antistoffer
DK2521736T3 (da)	2019-10-28	Humaniserede antistoffer
HRP20181320T8 (hr)	2018-12-14	Ljudska anti-tau protutijela
CO6791565A2 (es)	2013-11-14	Anticuerpos anti-notch1
DK3178851T3 (da)	2020-07-27	Anti-cd40-antistoffer
CR20130228A (es)	2013-09-18	Anticuerpos neutralizadores anti-ccl20
LT3275896T (lt)	2021-10-11	Antikūnų gavimo procesas
PT2736340T (pt)	2018-03-22	Biocontrolo de nemátodos
DK3202789T3 (da)	2020-05-18	Anti-vla-4-antistoffer
IL225346B (en)	2020-09-30	Serum preparation
HUE043576T2 (hu)	2019-08-28	Antitestek notum pektinacetilészterázhoz
EP2578316A4 (en)	2016-06-29	PIPETTE
CO6841994A2 (es)	2014-01-20	Anticuerpos
FR2956419B1 (fr)	2015-01-16	Elements de construction calorifuges
FR2955136B1 (fr)	2012-01-20	Arret de vantail
UA21042S (uk)	2010-10-25	Комплект бланків
IT1400965B1 (it)	2013-07-05	Polimorfi di fexofenadina